$Viking Therapeutics(VKTX.US)$
Results from the 28-day MAD study highlighted positive signs of clinical activity after oral VK2735 treatment. The group receiving VK2735 showed a decrease in average body weight compared to baseline, by as much as 5.3%. Compared to placebo, the average body weight of the group receiving VK2735 also decreased by as much as 3.3%. For doses greater than or equal to 10 mg, the average weight loss after placebo was maintained or improved on day 34, six days after the last dose of VK2735, as much as 3.6% compared to placebo. An exploratory evaluation of the proportion of subjects who lost at least 5% of their weight after 28 days showed that as many as 57% of those treated with VK2735 lost more than 5% of their weight, compared to 0% with placebo. Based on an initial assessment of the weight loss trajectory, the company believes that treatment over 28 days can lead to further weight loss.

“These first phase results highlight the promising early weight loss and tolerability of VK2735 in oral tablet doses,” said Dr. Brian Lien, CEO of Viking. “We think these data suggest that, at possibly higher doses, it may result in longer treatment times

$PDD Holdings(PDD.US)$PDD agency Jefferies raised its rating to the “buy” target price to $157.

$Broadcom(AVGO.US)$ J.P. Morgan raised Broadcom's target share price from $1550.00 to $1,700.00 per share

$Broadcom(AVGO.US)$ In the first fiscal quarter, the company generated $4.815 billion in cash from operations and had capital expenses of $122 million. The company spent $8.29 billion on share buybacks and removals, including $7.176 billion for 6.7 million share repurchases and $1,114 billion in withholding taxes associated with the quarter's net settlement equity rewards (equivalent to approximately 1 million shares withheld).
On December 29, 2023, the company paid a cash dividend of US$5.25 per share, totaling US$2,435 million.
Chief Legal and Corporate Affairs Officer Mark David Brazier acquired 16,375 common shares on March 5, 2024. The shares have a face value of $0.001 and were purchased free of charge, which suggests that this may be part of the executive's compensation package. Following this deal, Brazeal's direct shareholding in Broadcom increased to a total of 52,393 shares. The deal has been marked as completed.

$Viking Therapeutics(VKTX.US)$ VKTX [Why did it drop] -16%, as its competitor drug giant NVO Novo Nordisk will launch the obesity drug Wegovy in Japan to address Japan's growing weight problem. Novo Nordisk's chief strategy officer said earlier at the Capital Markets Day event that the first phase of the trial of the experimental drug Amycretin (Amycretin) showed participants lost 13.1% of their body weight after 12 weeks. Investors were thrilled. Additionally, the agency Jefferies gave a purchase evaluation of Viking Therapeutics, with a target price of $110.

$Taiwan Semiconductor(TSM.US)$ TSM J.P. Morgan notes that thanks to tightly integrated packaging technology, leading process technology, and the broadest customer ecosystem, TSMC's moat in the field of Al semiconductors appears to be wider than before.

$The Kroger(KR.US)$KR's stock price hit a two-year high, profit exceeded expectations, revenue greatly exceeded expectations, and will continue to acquire Alberstons.

$NVIDIA(NVDA.US)$ NVDA also had insiders cash out at a high rate, and two Nvidia directors sold $180 million in shares.

$EVgo Inc(EVGO.US)$EVGO's fourth-quarter revenue beat expectations, and charging revenue tripled.

$Palantir(PLTR.US)$The U.S. Army... confirmed that the enterprise software company's subsidiary has won a two-year contract and will begin the third phase of its next-generation target-targeting system.